Lupin gets USFDA approval for Cefdinir Suspension

BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, 2 June 2006: Lupin Ltd. announced that the U.S. Food and Drug Administration (US FDA) has approved the Company's Abbreviated New Drug Application (ANDA) for Cefdinir Suspension 125mg/5mL. Cefdinir is a third generation cephalosporin administered orally to treat a wide variety of bacterial infections.

Cefdinir is being marketed by Abbott under the Omnicef® brand name. As per IMS, the sales of the Omnicef® Suspension 125 mg/5mL were $137 million and the combined sales for capsules and suspensions were US$634 million (MAT Dec. 2005).

"The approval of our Cefdinir Suspension and the recent approval for the Capsule form by the US FDA reinforces Lupin's ability on submitting high quality dossiers and gaining approvals in time. This approval further strengthens our position in the Cephalosporins business in the US," said Dr. Kamal Sharma, Managing Director, Lupin.

Lupin is the first company to receive ANDA approval for Cefdinir for both, Capsule and Suspension forms. With this approval, Lupin now has 12 ANDAs approved by the USFDA.

About Lupin

Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the financial year ended March 2006, the Company's Revenues and Profit after Tax were Rs.16,610 million (US$ 375 million) and Rs.1,827 million (US$ 41 million) respectively.

For further information contact:
Raju Kane
The Source
Tel. +91 22 24901327/28
Telefax: +91 22 24901325
Mobile: +91 98200 45656
E-mail: rajukane@sourcepr.com